SecBot SecBot

CTMX drug pipeline

CytomX Therapeutics, Inc. · 2 rated drugs
$1.99
−2.7% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 bullish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 1
Time to marketIf the Phase 1 update supports the registrational study planned for H1 2027, a potential FDA approval would likely be several years away, assuming successful pivotal trial execution. The Fast Track designation could accelerate timelines, but the drug is still in Phase 1 development.

Varseta-M varsetatug masetecan Updated Nov 8

What to watch

The next major catalyst is the Phase 1 monotherapy data update in mCRC expected in January 2027 (roughly 2 months away). Positive data could support the planned registrational study start in H1 2027 and drive significant upside given the stock trades near cash value. Disappointing efficacy or safety signals could delay the pivotal program and pressure the stock toward its 52-week low of $2.11.

Bull case
  • Phase 1 dose expansion data showed promising 20-32% response rates and median PFS of 6.8-7.1 months in heavily pretreated late-line mCRC, outperforming standard-of-care options.
  • FDA granted Fast Track Designation in August 2026, which enables more frequent agency interactions and potential accelerated approval pathways.
  • Varseta-M is the only EpCAM-directed ADC in clinical development, targeting a broadly expressed tumor antigen with a differentiated Probody masking technology designed to reduce off-tumor toxicity.
Bear case
  • Phase 1 data is still early; the 20-32% response rate comes from a small, non-randomized expansion cohort and may not replicate in larger trials.
  • High-grade diarrhea is a known adverse event for topoisomerase-1 inhibitor ADCs and could limit tolerability or require dose modifications.
  • The stock trades near its 52-week low of $2.11, reflecting skepticism about whether early data will translate into a registrational program.
● neutral
Impact
PhasePhase 1
Time to marketCX-801 is in early Phase 1 dose-escalation. Even if Phase 1 completes successfully, it would need to advance through Phase 2 and potentially Phase 3 trials before any regulatory filing. Approval is likely several years away, if the program succeeds.

CX-801 conditionally activated interferon alpha-2b Probody Updated Nov 8

What to watch

CX-801 has no announced near-term catalyst. The next meaningful event for CytomX overall is the Varseta-M Phase 1 monotherapy data update in metastatic colorectal cancer expected in January 2027, which will likely drive the stock more than any CX-801 news. Watch for any CX-801 dose-escalation updates or expansion cohort announcements, but the program is early-stage and secondary to Varseta-M.

Bull case
  • Initial Phase 1 biomarker data presented at SITC 2025 showed tumor-selective activation of interferon signaling, validating the Probody masking approach in patients who had failed prior checkpoint therapy.
  • The combination with KEYTRUDA (pembrolizumab) addresses a large market opportunity in metastatic melanoma, where interferon-based therapies could complement PD-1 inhibition.
  • CytomX has a strong cash runway into 2H 2028 ($348M), providing funding for CX-801 development without near-term dilution risk.
Bear case
  • CX-801 is still in early Phase 1 dose-escalation with no efficacy data reported yet; the biomarker data only showed target engagement, not tumor responses.
  • Interferon alpha therapies have historically had significant toxicity and limited commercial success; the Probody masking may not fully overcome these challenges.
  • CX-801 is a secondary pipeline priority behind Varseta-M (CX-2051), which is the company's lead asset and primary value driver.